Related Experiment Video

Updated: Oct 30, 2025

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

3.6K

Clinical Trial Considerations in Neuro-oncology

Eudocia Q Lee1

  • 1Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. eqlee@partners.org.

Current Treatment Options in Oncology
|July 2, 2021
PubMed
Abstract

Insights

Improving clinical trials in neuro-oncology is crucial for developing new treatments. Key strategies include standardizing assessments, creating guidelines, decentralizing trials, and refining eligibility criteria to speed up regulatory approval.

Area of Science:

  • Neuro-oncology
  • Clinical trial methodology
  • Regulatory science

Background:

  • Clinical trials are essential for discovering novel cancer therapies.
  • The process for regulatory approval of new treatments is often lengthy and complex.
  • Challenges in neuro-oncology clinical trials hinder rapid therapeutic advancement.

Purpose of the Study:

  • To outline key strategies for enhancing the efficiency and interpretability of neuro-oncology clinical trials.
  • To address the complexities hindering timely drug development and approval in brain tumor research.

Main Methods:

  • Review of current practices and challenges in neuro-oncology clinical trials.
  • Identification of proposed improvements focusing on standardization and logistical enhancements.
  • Analysis of potential impacts of revised patient eligibility criteria.

Main Results:

  • Standardization of response assessment improves data consistency.
  • Consensus guidelines streamline clinical trial conduct.
  • Decentralization and revised eligibility criteria can accelerate patient accrual.
  • Addressing barriers to accrual is vital for trial completion.

Conclusions:

  • Implementing standardized response assessment and consensus guidelines enhances trial interpretability.
  • Decentralizing trials and optimizing eligibility criteria can significantly improve efficiency.
  • These combined efforts are critical for accelerating the development of new neuro-oncology treatments.
Keywords:
Clinical trial accrualClinical trial designClinical trial disparitiesClinical trialsResponse assessment

More Related Videos

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy10:10

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy

Published on: October 18, 2011

12.8K
Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging11:09

Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging

Published on: July 13, 2010

39.8K

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.0K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
9.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.3K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
214